☆ 4.7 Editorial Material

First-line treatment in metastatic colorectal cancer: Important or crucial?

EUROPEAN JOURNAL OF CANCER (2017)

Get Full Text
Add to Collection

Journal

EUROPEAN JOURNAL OF CANCER
Volume 84, Issue -, Pages 363-366

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2017.09.001

Keywords

-

Categories

Oncology

Funding

  1. Celgene
  2. Teva
  3. Boehringer-Ingelheim
  4. Roche
  5. Amgen
  6. Sanofi-Aventis
  7. Menarini
  8. Merck Serono
  9. Bayer
  10. Lilly
  11. MSD
  12. Daiichi Sankyo
  13. Novartis
  14. Prestizia

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.